

PRODUCT INFORMATION




AP26113

Item No. 19778

CAS Registry No.: 1197953-54-0
Formal Name: 5-chloro-N⁴-[2-(dimethylphosphinyl)phenyl]-N²-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine

Synonym: Brigatinib
MF: C₂₉H₃₉ClN₇O₂P
FW: 584.1
Purity: ≥98%
UV/Vis.: λ_{max}: 284 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AP26113 is supplied as a crystalline solid. A stock solution may be made by dissolving the AP26113 in the solvent of choice, which should be purged with an inert gas. AP26113 is soluble in organic solvents such as ethanol and dimethyl formamide. The solubility of AP26113 in these solvents is approximately 0.1 mg/ml.

AP26113 is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

AP26113 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK; IC₅₀ < 100 nM in Ba/F3 cells).^{1,2} It is a pan-ALK inhibitor that also inhibits several ALK mutants that confer resistance to other ALK inhibitors, such as crizotinib (Item No. 12087), ceritinib (Item No. 19374), and CH5424802 (Item No. 18516).^{1,2} AP26113 blocks ALK activity and reduces growth in neuroblastoma cells, mouse xenograft, and *Drosophila* model systems harboring constitutively active ALK variants.³

References

- Ceccon M., Mologni L., Bisson W., *et al.* Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. *Mol. Cancer Res.* **11(2)**, 122-132 (2013).
- Katayama, R., Khan, T. M., Benes, C., *et al.* Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *PNAS USA* **108(18)**, 7535-7540 (2011).
- Siaw, J. T., Wan H., Pfeifer, K., *et al.* Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, *Drosophila* and mice. *Oncotarget* **7(20)**, 29011-29022 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/22/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM